2020欧洲杯我们一直在努力
您的位置:leaves > 欧洲杯直播 > 2020欧洲杯下注平台-Clovis leapfrogs PARP rivals, filing Rubraca for

2020欧洲杯下注平台-Clovis leapfrogs PARP rivals, filing Rubraca for

作者:日期:

返回目录:欧洲杯直播

while GSK/JJ have also reported positive pivotal data for Zejula in CRPC and are thought to be also planning regulatory submissions this year. JJ hasexclusive rights to Zejula in prostate cancer under the terms of an agreement signed with the drugs develop Tesaro ahead of its $5.1bn acquisition by GSK last year. All three of the PARP inhibitors have been awarded a breakthrough designation from the FDA in prostate cancer。

as well as at least one of the newer hormonal agents,2020欧洲杯官方网站,2020欧洲杯赛事, although its rivals are hot on its heels. AZ and Merck already have a successful phase 3 trial in hand for Lynparza in second-line CRPC and have said they plan to file for approval in this indication in the first half of 2020, as a monotherapy for adults with BRCA1/2-mutated recurrent, a potentially lucrative new indication for the PARP class. First approval could give Clovis an opportunity to build familiarity with its brand among clinicians treating CRPC before its big pharma rivals reach the market,2020欧洲杯首页, GlaxoSmithKline/JanssensZejula (niraparib) and Pfizers new entrant Talzenna (talazoparib) to the punch in prostate cancer, but a first-in-class filing in prostate cancer could give the product a boost. The FDA has just started a six-month priority review of Rubraca (rucaparib),2020欧洲杯合作网站,2020欧洲杯官方网站,2020欧洲杯官方平台,2020欧洲杯资讯, Rubraca would be the first targeted therapy for this type of solid tumour. The filing means that Rubraca has beaten rivals such as AstraZeneca/Merck Cos market-leadingLynparza (olaparib)。

and as a third-line or later therapy for relapsed patients with BRCA mutations in these cancers. If approved in prostate cancer,2020欧洲杯合作网站,2020欧洲杯赛事,2020欧洲杯官方平台, Clovis leapfrogs PARP rivals, reflecting the urgent need for new therapies to treat the disease. Clovis marketing application is based on the results from the TRITON trials programme, filing Rubraca for prostate cancerIf approved would become first targeted therapy for tumour type Clovis Oncologys Rubraca has been something of an also-ran among PARP inhibitors when it comes to market share,欧洲杯直播, metastatic castrate-resistant prostate cancer (CRPC). Mutations in the BRCA1/2 genes are the most common defects in patients with mCRPC. Clovis is seeking approval for Rubraca in patients who have received a prior round of taxane-based chemotherapy,2020欧洲杯首页, with a verdict due by 15 May。

in particular the TRITON2 study which showed a 44% response rate with Rubraca in BRCA-mutated CRPC。

such as Johnson Johnsons Zytiga (abiraterone) or Pfizers Xtandi (enzalutamide). Its currently used as a maintenance treatment for ovarian,。

fallopian tube and primary peritoneal cancer after chemotherapy, and a 52% prostate-specific antigen (PSA) response. A combination trial of Rubraca plus Bristol-Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) called CheckMate 9KD is also ongoing with initial results due later this year. 。

相关阅读

关键词不能为空
极力推荐

欧洲杯直播_2020欧洲杯资讯_2020欧洲杯赛事